CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Guanfacine hydrochloride

Last Updated: August 27, 2013
Result type: Reports
Project Number: SR0349-000
Product Line: Reimbursement Review

Generic Name: Guanfacine hydrochloride

Brand Name: Intuniv XR

Manufacturer: Shire Canada Inc.

Therapeutic Area: Attention-deficit/hyperactivity disorder (ADHD)

Indications: Attention-deficit/hyperactivity disorder (ADHD)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: September 24, 2014

Recommendation Type: Do not list